Table 3. SLR versus CFRT or SBRT for high-risk elderly stage I NSCLC: a meta-analysis of OS.
| End point | No. of studies | No. of patients | OR | 95% CI | Significance | Publication bias | Heterogeneity |
|---|---|---|---|---|---|---|---|
| SLR versus CFRT | |||||||
| 1-year survival | |||||||
| All studies combined | 5 | 891 | 2.30 | 1.57–3.37 | 0.0001 | 0.46 | 0.54 |
| PSM analysis | 2 | 706 | 2.01 | 1.34–3.03 | 0.001 | 0.87 | |
| None PSM analysis | 3 | 185 | 6.20 | 1.88–20.50 | 0.003 | 1.00 | |
| 2-year survival | |||||||
| All studies combined | 5 | 891 | 2.11 | 1.59–2.81 | 0.0001 | 0.31 | 0.11 |
| PSM analysis | 2 | 706 | 2.10 | 1.54–2.87 | 0.0001 | 0.05 | |
| None PSM analysis | 3 | 185 | 2.18 | 1.08–4.40 | 0.03 | 0.15 | |
| 3-year survival | |||||||
| All studies combined | 5 | 891 | 1.54 | 1.18–2.01 | 0.002 | 0.81 | 0.28 |
| PSM analysis | 2 | 706 | 1.53 | 1.14–2.06 | 0.005 | 0.71 | |
| None PSM analysis | 3 | 185 | 1.59 | 0.87–2.91 | 0.14 | 0.09 | |
| 5-year survival | |||||||
| All studies combined | 5 | 891 | 2.73 | 2.02–3.69 | 0.0001 | 0.81 | 0.67 |
| PSM analysis | 2 | 706 | 2.80 | 1.99–3.94 | 0.0001 | 0.86 | |
| None PSM analysis | 3 | 185 | 2.50 | 1.32–4.72 | 0.05 | 0.32 | |
| SLR versus SBRT | |||||||
| 1-year survival | |||||||
| All studies combined | 8 | 10465 | 1.64 | 1.02–2.64 | 0.04 | 1.00 | 0.05 |
| PSM analysis | 5 | 10027 | 1.44 | 1.32–1.57 | 0.0001 | 0.16 | |
| PSM analysis excluding reference 50 | 4 | 917 | 1.63 | 0.65–4.09 | 0.29 | 0.04 | |
| None PSM analysis | 3 | 438 | 4.62 | 1.66–12.86 | 0.003 | 0.06 | |
| 2-year survival | |||||||
| All studies combined | 8 | 10465 | 1.90 | 1.20–3.02 | 0.006 | 1.00 | 0.0001 |
| PSM analysis | 5 | 10027 | 1.95 | 1.26–3.02 | 0.003 | 0.003 | |
| PSM analysis excluding reference 50 | 4 | 917 | 2.15 | 0.98–4.75 | 0.06 | 0.002 | |
| None PSM analysis | 3 | 438 | 9.01 | 3.88–20.93 | 0.0001 | 0.08 | |
| 3-year survival | |||||||
| All studies combined | 9 | 10564 | 2.91 | 1.94–4.38 | 0.0001 | 0.75 | 0.0001 |
| PSM analysis | 6 | 10126 | 2.29 | 1.48–3.55 | 0.0001 | 0.0001 | |
| PSM analysis excluding reference 50 | 5 | 1016 | 2.17 | 1.21–3.87 | 0.009 | 0.007 | |
| None PSM analysis | 3 | 438 | 5.63 | 3.22–9.86 | 0.0001 | 0.05 | |
| 5-year survival | |||||||
| All studies combined | 6 | 10588 | 2.97 | 1.51–5.83 | 0.002 | 1.00 | 0.0001 |
| PSM analysis | 4 | 9803 | 3.74 | 1.92–7.26 | 0.0001 | 0.003 | |
| PSM analysis excluding reference 50 | 3 | 693 | 3.55 | 1.06–11.94 | 0.04 | 0.002 | |
| None PSM analysis | 2 | 347 | 1.83 | 0.37–9.13 | 0.46 | 0.03 | |
Abbreviations: CFRT: conventional fractionated radiotherapy; PSM: propensity-score matched; SBRT: stereotactic body radiation therapy; SLR: sublobar resection; OR: Odds ratio; CI: confidence interval.